Quote:
Originally Posted by Riverwild
http://pharmalive.com/News/index.cfm...categoryid=10#
Panel of multiple sclerosis experts provides best practice treatment recommendations for Tysabri.
Dec. 4, 2009-Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI® (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis. The panel provided recommendations focusing on appropriate patient selection and patient management. The recommendations, which recognize the significant efficacy of TYSABRI and the need to adequately treat patients who exhibit continued disease activity, are based on U.S. prescribing information and the panel's vast clinical experience in treating MS patients with TYSABRI. Recommendations not only take into account the need to adequately treat patients who exhibit continued disease activity, but also the need to weigh the treatment's benefit with potential risks...
It's been very quiet in here. I hope everyone's doing well and that you're all ready for whatever your holiday plans are! 
|
River,
Thanks for the link. Good info but likely subject to significant change once the JC Virus Antibody assay is rolled out in the near future.
Chris